Curanex Pharmaceuticals (CURX) EPS (Basic) (2024 - 2025)
Curanex Pharmaceuticals' (CURX) quarterly EPS (Basic) came in at -$0.12 in Q4 2025, down 479.64% YoY from $0.03 in Q4 2024, and down 160.22% on a QoQ basis from -$0.05 in Q3 2025.
Curanex Pharmaceuticals (CURX) EPS (Basic) (2024 - 2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has 2 years of EPS (Basic) data on file, last reported at -$0.12 in Q4 2025.
- Quarterly EPS (Basic) fell 479.64% year-over-year to -$0.12 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$0.19 (changed N/A YoY) and the FY2025 annual result came in at -$0.21, down 452.04% from the prior year.
- EPS (Basic) slipped to -$0.12 in Q4 2025, from -$0.05 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$0.01 in Q2 2025 to a low of -$0.12 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.18 |
| 10 | Curanex Pharmaceuticals | 6.02 Mn | 1.02 Mn | - | -2.43 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.12 |
| Sep 30, 2025 | -0.05 |
| Jun 30, 2025 | -0.01 |
| Dec 31, 2024 | -0.02 |
| Sep 30, 2024 | -0.04 |